Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter
NCT ID: NCT03437538
Last Updated: 2019-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2018-05-21
2019-04-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The major aim of this study is to compare the reduction ratio of middle molecules, during a single hemodialysis session with MCO-filter, compared to hemodiafiltration (HDF) with standard high-flux filter.
Secondary aims are to compare the reduction ratio of small and large molecules between the treatments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter.
NCT03416192
Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal
NCT03938285
Modulation of Inflammation by Medium Cut Off Membranes
NCT03270371
Comparison of MCO HD on Markers of Vascular Health Compared With On-Line Haemodiafiltration
NCT03510520
PERCI- Medium Cut Off (MCO)
NCT02084381
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
First MCO-HD, then High-flux-HDF
Participants with ongoing HDF-treatments will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF
MCO-HD
Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
High-flux HDF
Measurements will be done during a single hemodiafiltration session with standard high-flux filter
First High-flux-HDF, then MCO-HD
Participants with ongoing HDF-treatments will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD
MCO-HD
Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
High-flux HDF
Measurements will be done during a single hemodiafiltration session with standard high-flux filter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MCO-HD
Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
High-flux HDF
Measurements will be done during a single hemodiafiltration session with standard high-flux filter
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CRP \<30
* No Acute Myocardial Infarction within 3 months.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lund University
OTHER
Region Skane
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anders Christensson, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Region Skane, Lund University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Skane University Hospital
Malmo, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017/830/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.